Skip to main content
Premium Trial:

Request an Annual Quote

Hyseq Losses Dwindle, Revenues Climb for Q2

NEW YORK, July 25-Hyseq today reported a small decrease in net losses and a modest increase in revenues for the second quarter of 2002.


For the three months ended June 30, 2002, Hyseq reported a net loss of $8.1 million, or $0.37 per share. Losses for the second quarter 2001 were $8.4 million, or $0.55 per share.


Hyseq said that its revenues for the quarter had climbed to $11.9 million from $11.6 million for the equivalent quarter in 2001.


During the second quarter of 2002, the company also pocketed about $15 million from a private stock placement.


R&D expenditures dwindled slightly, from $11 million in the second quarter of 2001 to $10.7 million in Q2 2002.


Hyseq said it had $11.8 million in cash on hand as of June 30, 2002.


For more information, see the company quarterly report.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.